RRC ID |
66241
|
著者 |
Uemura K, Sasaki M, Sanaki T, Toba S, Takahashi Y, Orba Y, Hall WW, Maenaka K, Sawa H, Sato A.
|
タイトル |
MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2.
|
ジャーナル |
Sci Rep
|
Abstract |
Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.
|
巻・号 |
11(1)
|
ページ |
5376
|
公開日 |
2021-3-8
|
DOI |
10.1038/s41598-021-84882-7
|
PII |
10.1038/s41598-021-84882-7
|
PMID |
33686154
|
PMC |
PMC7940632
|
MeSH |
Angiotensin-Converting Enzyme 2 / metabolism*
Animals
Antiviral Agents / pharmacology*
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment
Cell Engineering*
Cell Line
Drug Discovery*
Humans
Models, Biological*
SARS-CoV-2 / drug effects
SARS-CoV-2 / physiology*
Viral Proteins / biosynthesis
Virus Replication / drug effects
|
IF |
3.998
|
リソース情報 |
ヒト・動物細胞 |
CACO-2(RCB0988)
293T(RCB2202) |